August 8, 2011 / 1:53 PM / 7 years ago

Merck gets subpoena tied to marketing of 3 drugs

NEW YORK (Reuters) - The Department of Justice has issued Merck & Co (MRK.N) a subpoena seeking information about the drugmaker’s marketing of three drugs acquired in its 2009 merger with Schering-Plough Corp.

The subpoena, which Merck disclosed in its quarterly securities filing, involves the brain cancer drug Temodar, hepatitis C medicine Peg-Intron, and Intron A, which is approved for hepatitis C as well as for forms of cancer.

The subpoena seeks information from January 2004 to the present “in a federal health care investigation under criminal statutes,” Merck said in its filing. The company said it is cooperating with the probe.

Reporting by Lewis Krauskopf, editing by Gerald E. McCormick

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below